Wegovy for women: How it works, why results differ, and what women need to know

GLP-1 medications are reshaping how the medical community thinks about weight, metabolism, and chronic disease. Wegovy - the semaglutide-based injection and pill approved specifically for weight management - is one of the most studied drugs in this class. But a closer look at the data reveals something the headlines often miss: Wegovy doesn’t work the same way in women as it does in men.

Women tend to lose more weight on semaglutide. Women also face a distinct set of considerations - from how the medication interacts with hormonal health and the menstrual cycle, to what it means for fertility, contraception, and life stages like PCOS, perimenopause, and menopause.

What is Wegovy, and how does it work?

Wegovy is a prescription medication approved by the FDA for chronic weight management in adults. Its active ingredient is semaglutide - the same molecule used in Ozempic for type 2 diabetes, at a higher dose and with a different approved indication.

Semaglutide belongs to a drug class called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It signals fullness to the brain, slows gastric emptying, and improves how the body manages blood sugar. Wegovy mimics this hormone and sustains its effects well beyond what the body would produce on its own.

The practical outcome is a significant reduction in hunger and appetite — and, for many people, a reduction in what’s been coined “food noise”: the persistent mental preoccupation with food, cravings, and eating that makes sustained dietary change so difficult. This isn’t a behavioral fix. It’s a physiological one.

Wegovy works upstream of willpower — at the hormonal level where hunger is actually generated.

Why women consider Wegovy

Weight management is rarely straightforward for women, and the reasons are largely biological. Hormonal fluctuations across the menstrual cycle affect hunger, cravings, and energy expenditure. Conditions like PCOS and hypothyroidism - which disproportionately affect women - create insulin resistance that makes standard caloric approaches insufficient. The hormonal shifts of perimenopause and menopause redistribute fat, slow metabolism, and worsen insulin sensitivity in ways that often feel sudden and disconnected from lifestyle. And for many women, decades of weight cycling, restrictive dieting, or being told to simply “eat less and move more” have produced frustration, not results.

Wegovy addresses a different layer of the problem. Rather than imposing behavioral change through restriction, it works at the hormonal level - reducing the physiological drive to overeat and improving metabolic function in ways that make sustained weight management more achievable. For women whose weight challenges are rooted in insulin resistance, hormonal dysregulation, or a metabolism altered by life transitions, this mechanism represents a meaningful shift in what’s available.

Deciding whether Wegovy is appropriate, however, requires more than checking a BMI threshold. It requires understanding the full picture: root causes of weight changes, existing metabolic and hormonal conditions, cardiovascular risk, life stage, and long-term goals. That evaluation is where medically supervised care makes the difference.

Wegovy is one component of Tia’s Metabolic Health & Weight Loss Program - a women’s-specific program designed to identify the root causes of weight and metabolic changes, screen for insulin resistance and related conditions, and build a personalized, evidence-based plan that may include GLP-1 medications like Wegovy when clinically appropriate. The program includes a comprehensive metabolic assessment, ongoing medical monitoring, and long-term follow-up - not a one-time prescription.

Available in-person in San Francisco, Los Angeles, and Scottsdale, and virtually across California, Arizona, New York, Massachusetts, New Jersey, and Connecticut.

How is Wegovy taken? Injection vs pill

Wegovy is currently available in two forms, and understanding the difference matters when considering whether it’s the right fit.

The Wegovy injection has been FDA-approved since 2021. It is administered once weekly as a subcutaneous injection - under the skin of the abdomen, thigh, or upper arm - using a small pre-filled pen. The weekly schedule makes adherence straightforward for most people, and the injection is generally well-tolerated once the titration period is complete.

The Wegovy pill (oral semaglutide 25 mg) was FDA-approved in December 2025, making it the first oral GLP-1 medication ever approved for weight loss. It is taken once daily, at least 30 minutes before the first meal or drink of the day, with no more than 4 oz of plain water. In clinical trials, the pill produced an average weight loss of 16.6% — comparable to the injection.

Quick comparison:

• Injection: Once weekly · FDA-approved 2021 · Most long-term data · Max dose 2.4 mg
• Pill: Once daily · FDA-approved December 2025 · ~16.6% average weight loss in trials · No needles required

Both forms require a prescription.

Wegovy results across different life stages

One of the more significant findings for women is that Wegovy’s effectiveness doesn’t decline with age or hormonal stage. A 2025 pooled analysis showed meaningful weight loss across all menopause stages:

• Pre-menopausal women: 18.2% average weight loss
• Peri-menopausal women: 15.0% average weight loss
• Post-menopausal women: 15.7% average weight loss

The hormonal changes of perimenopause — declining estrogen, increasing insulin resistance, redistribution of fat toward the abdomen — are often precisely what makes weight management feel impossible during midlife. Wegovy’s mechanism addresses these metabolic drivers directly, which may help explain why results remain strong even after menopause.

It's essential to determine whether you have actually entered perimenopause or menopause, as symptoms can overlap with other conditions. Tia's Perimenopause/Menopause Assessment is the best place to start.

Possible Wegovy benefits for women

Weight loss is one outcome of Wegovy. But for women, the implications extend into multiple intersecting areas of health - many of which are undertreated and poorly addressed by standard weight management approaches.

1. PCOS and insulin resistance

Polycystic ovary syndrome (PCOS) affects an estimated 7–10% of women of reproductive age, making it the most common hormonal disorder in this population. Insulin resistance is central to the condition — driving irregular cycles, elevated androgens, stubborn weight gain, and increased long-term risk of type 2 diabetes and cardiovascular disease.

Wegovy’s mechanism directly targets insulin resistance, and the downstream effects can be substantial. Research shows that losing just 5–10% of body weight can lower androgen levels, regulate menstrual cycles, and restore ovulation in women with PCOS. In one clinical study, nearly 80% of women with PCOS on semaglutide lost at least 5% of body weight, with corresponding improvements in blood sugar control and cycle regularity.

A separate randomized trial found that combining semaglutide with metformin outperformed metformin alone — producing greater weight loss, improved insulin sensitivity, better cycle regularity, and higher rates of natural pregnancy.

Note: Wegovy is not FDA-approved specifically for PCOS, but it can be prescribed off-label for women who meet the weight-related eligibility criteria.

2. Cardiovascular protection

In March 2024, Wegovy became the first weight loss medication ever approved by the FDA to reduce cardiovascular risk. In the SELECT trial — which followed over 17,600 people across several years — semaglutide reduced the risk of heart attack, stroke, or cardiovascular death by 20% in adults with existing heart disease and obesity or overweight.

Importantly, a significant portion of this cardiovascular benefit appears to occur independently of weight loss — suggesting that semaglutide has direct protective effects on the cardiovascular system beyond fat reduction alone. For postmenopausal women, who face sharply elevated cardiac risk as estrogen declines, this distinction is clinically meaningful.

3. Fatty liver disease

In 2025, Wegovy received an additional FDA approval for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) — a serious form of fatty liver disease driven by insulin resistance. Fatty liver is more prevalent among women in perimenopause and menopause, as metabolic shifts increase visceral fat accumulation. Wegovy’s approval in this indication extends its clinical utility well beyond weight management.

4. Brain health and cognition

Emerging research suggests GLP-1 receptor agonists may have neuroprotective properties. Early studies indicate a potential role in slowing cognitive decline in Alzheimer’s and Parkinson’s disease. The biological connection between metabolic health and cognitive function is well-established, and semaglutide’s impact on insulin sensitivity and inflammation may contribute to these effects. This area of research is still developing, but the early signals are compelling.

5. Perimenopause and menopause

The metabolic disruption of the menopause transition— worsening insulin resistance, increased visceral adiposity, destabilized blood sugar — is frequently undertreated. Lifestyle interventions alone are often insufficient. The 2025 pooled analysis confirming that semaglutide produces meaningful weight loss across all menopause stages is significant: it means Wegovy’s effectiveness is not compromised by the hormonal changes that typically make weight management harder during this period.

6. Fertility

Losing 5–10% of body weight can restore regular ovulation in women whose cycles have been disrupted by obesity-related hormonal imbalance or PCOS. This is the mechanism behind the widely reported “Ozempic baby” phenomenon — unexpected pregnancies among women on GLP-1 medications. Wegovy does not act as a fertility drug, but by improving the metabolic conditions required for consistent ovulation, it can indirectly restore fertility.

According to research from UT Southwestern, 44% of women on semaglutide in the SELECT trial lost more than 10% of body weight within two years — a threshold shown to meaningfully improve ovulatory function. Women not intending to conceive should be aware of this effect when making contraception decisions.

7. Appetite, cravings, and emotional eating

Women disproportionately report emotional eating, stress-driven food seeking, and cyclical cravings that intensify around menstruation, perimenopause, and periods of elevated cortisol. Wegovy acts on the brain’s satiety centers in ways that reduce not just hunger, but the compulsive pull toward food as a coping mechanism. Clinical reports consistently describe a reduction in food preoccupation that dietary interventions alone rarely achieve.

8. Migraine relief: a promising emerging benefit

Migraine affects women at roughly three times the rate of men — and it is one of the most undertreated conditions in women’s health. A growing body of research now suggests that GLP-1 medications including Wegovy may offer meaningful relief for chronic migraine sufferers, through mechanisms that appear to be independent of weight loss.

The strongest signal to date comes from a large real-world study of approximately 22,000 people with chronic migraine, presented at the American Academy of Neurology Annual Meeting in March 2026. Researchers found that those who started GLP-1 drugs were 10% less likely to visit the emergency department and 14% less likely to be hospitalized over the following year, compared to those starting topiramate - a standard preventive migraine medication.

Earlier clinical data points to a plausible mechanism. A 2025 pilot study published in Headache: The Journal of Head and Face Pain found that liraglutide - a GLP-1 closely related to semaglutide - reduced average monthly migraine days from 19.8 to 10.7 in patients with chronic migraine unresponsive to at least two prior preventive treatments.

Wegovy is not FDA-approved for migraine, and controlled trials specifically on semaglutide are still needed. But for women managing chronic migraine alongside obesity or metabolic conditions, this is a clinically meaningful overlap worth raising with a provider.

Wegovy side effects in women

Gastrointestinal effects

The most common side effects of Wegovy are gastrointestinal: nausea, diarrhea, constipation, bloating, and reduced appetite. These are most pronounced during dose escalation and typically diminish as the body adjusts. The gradual titration schedule — starting at 0.25 mg and increasing over 16 weeks — is designed specifically to minimize this.

Strategies that reduce GI side effects:

• Taking the weekly injection in the evening so peak nausea occurs during sleep
• Eating smaller, lower-fat meals during the titration period
• Avoiding high-fat, fried, or heavily seasoned foods which worsen nausea
• Maintaining consistent hydration to prevent compounding issues

Women experience more nausea than men

Clinical trial data shows that nausea and vomiting are reported at higher rates in women than men on semaglutide. Women with a history of motion sickness, pregnancy-related nausea, or gastrointestinal sensitivity may want to flag this with a provider before initiating treatment — not to avoid Wegovy, but to have a management plan in place from the outset.

Hair loss and shedding

Hair loss is one of the most searched Wegovy side effects online - and one of the most misunderstood. The clinical reality is more reassuring than the conversation suggests.

First, the numbers: in Wegovy’s own clinical trials, hair loss was reported in 3% of adults taking Wegovy, compared to 1% taking placebo. That is a real signal, but it means the vast majority of people on Wegovy — 97% — do not experience it. It is not a common side effect by clinical definition, and it is not permanent.

When it does occur, the mechanism is well understood. It is telogen effluvium - a temporary disruption of the hair growth cycle triggered by the physiological stress of rapid weight loss, identical to what occurs after childbirth, major surgery, or crash dieting. The medication itself is not attacking hair follicles. The shedding typically begins two to four months after significant weight loss starts and resolves within six to twelve months once weight stabilizes. It is diffuse and across the scalp, not patterned.

Women appear to be more susceptible than men. A 2025 preprint study analyzing over 3,000 patients found that women on semaglutide had more than twice the risk of hair loss compared to women on an alternative weight loss medication, while the signal in men was not statistically significant.

Nutritional factors significantly influence severity. The most effective mitigation strategies are:

• Maintaining adequate protein intake — a minimum of 70–100g per day
• Testing for and correcting deficiencies in iron, zinc, biotin, and vitamin D
• Prioritizing gradual weight loss over maximum speed, which reduces physiological stress

Wegovy & oral contraceptive absorption

One of the most clinically important and underreported interactions of Wegovy for women is its effect on oral contraceptive pill (OCP) absorption. Because semaglutide slows gastric emptying, it can impair how completely OCPs are absorbed, potentially reducing their contraceptive efficacy. This is most relevant:

• During the first 4 weeks after initiating Wegovy
• For 4 weeks following each dose increase

Non-oral contraceptive methods — including IUDs, implants, patches, vaginal rings, and barrier methods — are not affected by this interaction. Wegovy’s FDA label advises discontinuing the medication at least two months before attempting to conceive. Women on OCPs who are starting Wegovy should discuss contraception management with their provider before initiation.

Wegovy use during pregnancy

Wegovy is not recommended during pregnancy. Animal studies have raised concerns about fetal development, and human safety data remains insufficient to establish a risk-free profile. Novo Nordisk has established a pregnancy registry for Wegovy to collect real-world safety data, though results have not yet been published. Current clinical guidance recommends:

• Discontinuing Wegovy at least 2 months before attempting conception to allow full clearance
• Continuing reliable contraception until actively trying to conceive, given that weight loss may restore ovulation unexpectedly
• Stopping the medication immediately and consulting a provider upon confirmed pregnancy
• For women with PCOS planning pregnancy, coordinating a transition plan with both gynecology and endocrinology before stopping Wegovy

Wegovy and breastfeeding

No human safety data exists for semaglutide use during breastfeeding. Out of caution, Wegovy is not recommended while nursing. Providers can advise on alternative weight management approaches compatible with lactation.

The bottom line

Wegovy is one of the most well-studied medications in the history of obesity treatment. For women specifically, the evidence is clear and compelling: semaglutide produces meaningful, sustained weight loss — and women consistently see stronger results than men.

But the more complete picture is richer than the weight loss headline. For women managing PCOS, navigating perimenopause, carrying cardiovascular risk, or dealing with chronic migraine, or dealing with the metabolic consequences of hormonal change, Wegovy addresses biology that has historically been underdiscussed and undertreated. It is not a cure and it is not appropriate for everyone — but when prescribed thoughtfully as part of a comprehensive approach to women’s metabolic health, it is a tool with substantial potential.

Getting that evaluation right requires a provider who understands the full picture: the hormonal drivers, the life stage, the metabolic history, and the long-term goals — not just a BMI number. That is the difference between a prescription and a plan.

The right next step is a dedicated metabolic health assessment — a conversation that goes beyond the scale to examine root causes, screen for underlying conditions, and determine whether Wegovy or another GLP-1 is clinically appropriate.

Tia’s Metabolic Health & Weight Loss Program is built specifically for this evaluation: a women’s-focused program that includes comprehensive metabolic screening, hormonal assessment, and medically supervised access to GLP-1 medications when clinically indicated — with ongoing monitoring and long-term follow-up, not a one-time prescription. Available in-person in San Francisco, Los Angeles, and Scottsdale, and virtually across California, Arizona, New York, Massachusetts, New Jersey, and Connecticut. Schedule a Metabolic Health Assessment at Tia.